Elektrofi Inc., a biopharmaceutical delivery technology developer, has successfully raised $112.25 million in an upsized Series C financing round. This key funding was co-led by industry giants Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with contributions from Eli Lilly and other major investors in life sciences.
The Series C funds will be allocated to selecting commercial-scale Good Manufacturing Practice (GMP) manufacturing lines, an expansion that will support Elektrofi’s efforts to advance its groundbreaking Hypercon technology platform.
The Hypercon platform is planned to hyper-concentrate and stabilize biopharmaceuticals, enabling self-administration and, potentially, widening patient access to critical treatments.
The first GMP manufacturing line will be launched in early 2025, and with Phase 3 and additional GMP lines planned, Elektrofi is positioned to expedite the launch and distribution of its innovative pipeline.
“At Elektrofi, we envision a world in which patients have the independence they need—around how and where they take their medications—to live life on their terms,” said CEO Chase Coffman.
“The industry is on the cusp of a drug delivery revolution, and Elektrofi is proud to be leading it with Hypercon.”
Elektrofi’s mission is clear: transform drug delivery for patients worldwide. With a distinguished crew, board of directors, and top-tier investors, the company is poised to scale its proprietary platform and bring life-saving cures to market with remarkable speed.
